PCAS

Regulatory Filings • Jan 29, 2015

PCAS/Expansia has been nominated by UCB Pharma "Vendor of the year 2014"

Longjumeau, January 30, 2015

UCB is pleased to recognize PCAS Expansia for their Professional engagement and commitment to Quality and Operation Excellence during 2014. PCAS Expansia has demonstrated a strong commitment to meet UCB specific requirements by working proactively with UCB in an open minded and high flexible manner. This Excellent relationship has enabled enhancement of product capabilities and has highlighted opportunities to further increase value for UCB patients.

About UCB:

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.4 billion in 2013. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

About PCAS:

Founded in 1962, PCAS is an international fine and specialty chemicals group (165 million € net sales in 2013) that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of proprietary products based on intellectual property.